A 72-Year-Old Male with R/R Chronic Lymphocytic Leukemia

home / case-based-peer-perspectives / a-72-year-old-male-with-rr-chronic-lymphocytic-leukemia

Key opinion leader Andrew Lipsky, MD, reviews the case of a 72-year-old man with relapsed/refractory chronic lymphocytic leukemia and highlights the evolving treatment landscape of targeted therapy in this setting.

Expert on CLL

EP. 1: Case Overview: Relapsed/Refractory CLL Treated With a BTK Inhibitor

Andrew H. Lipsky, MD
June 27th 2023

Expert Andrew Lipsky, MD, reviews a patient case of relapsed/refractory chronic lymphocytic leukemia managed with BTK inhibition in the second-line setting.

Watch

Expert on CLL

EP. 2: Chronic Lymphocytic Leukemia: First-Line Treatment Armamentarium

Andrew H. Lipsky, MD
June 27th 2023

Focused discussion on the first-line treatment armamentarium available to patients diagnosed with chronic lymphocytic leukemia.

Watch

Expert on CLL

EP. 3: Role of BTK Inhibitors as Second-Line Therapy for Patients With CLL

Andrew H. Lipsky, MD
July 10th 2023

Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Watch

Expert on CLL

EP. 4: Clinical Trial Data in Relapsed/Refractory CLL: The ALPINE Trial

Andrew H. Lipsky, MD
July 10th 2023

Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Watch

Expert on CLL

EP. 5: Clinical Trial Data in Relapsed/Refractory CLL: The ELEVATE-RR Trial

Andrew H. Lipsky, MD
July 10th 2023

Shared insight on ELEVATE-RR, which utilized acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Watch

Expert on CLL

EP. 6: Role of Efficacy Data in Selecting Optimal Therapy for Patients With Relapsed/Refractory CLL

Andrew H. Lipsky, MD
July 10th 2023

Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.

Watch

Expert on CLL

EP. 7: Relapsed/Refractory CLL: CV Safety Data With Available Therapies

Andrew H. Lipsky, MD
July 10th 2023

Comprehensive insight to cardiovascular safety data with available therapies and how current understandings may impact the management of patients with relapsed/refractory chronic lymphocytic leukemia.

Watch